A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, EUROPEAN MULTICENTRE TRIAL OF TWO NEW BUDESONIDE FORMULATIONS FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS

(1) University Hospital Basel, Basel, Switzerland

(2) Center For Digestive Diseases Eppendorf, Hamburg, Germany

(3) Otto V. Guericke University, Magdeburg, Germany

(4) Klinikum Siloah, Hannover, Germany

(5) Klinikum Bayreuth, Bayreuth, Germany

(6) Israelitisches Krankenhaus, Hamburg, Germany

(7) University Hospital Of Leipzig, Leipzig, Germany

(8) Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany

(9) Klinikum Braunschweig, Braunschweig, Germany

(10) Gastroenterologist In Private Practice, Berlin, Germany

(11) University Hospital Leuven, Leuven, Belgium

(12) Deutsche Klinik Für Diagnostik, Wiesbaden, Germany

(13) Krankenhaus Martha-Maria Halle-Dölau, Halle (saale), Germany

(14) Az Sint-Lucas Brugge, Brugge, Belgium

(15) Dr. Falk Pharma Gmbh, Freiburg, Germany

(16) Swiss Eoe Research Group, Olten, Switzerland



This item was part of the Eosinophilic oesophagitis and other immune mediated upper GI diseases session at UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)